These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 33009062)

  • 1. Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome.
    Barberio B; Houghton LA; Yiannakou Y; Savarino EV; Black CJ; Ford AC
    Am J Gastroenterol; 2021 Feb; 116(2):362-371. PubMed ID: 33009062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Method to Classify and Subgroup Patients With IBS Based on Gastrointestinal Symptoms and Psychological Profiles.
    Black CJ; Yiannakou Y; Guthrie EA; West R; Houghton LA; Ford AC
    Am J Gastroenterol; 2021 Feb; 116(2):372-381. PubMed ID: 33110014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiological, Clinical, and Psychological Characteristics of Individuals with Self-reported Irritable Bowel Syndrome Based on the Rome IV vs Rome III Criteria.
    Black CJ; Yiannakou Y; Houghton LA; Ford AC
    Clin Gastroenterol Hepatol; 2020 Feb; 18(2):392-398.e2. PubMed ID: 31154027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of symptoms in irritable bowel syndrome with mixed bowel habit pattern.
    Su AM; Shih W; Presson AP; Chang L
    Neurogastroenterol Motil; 2014 Jan; 26(1):36-45. PubMed ID: 23991913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural History and Disease Impact of Rome IV Vs Rome III Irritable Bowel Syndrome: A Longitudinal Follow-Up Study.
    Goodoory VC; Houghton LA; Yiannakou Y; Black CJ; Ford AC
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):569-577.e3. PubMed ID: 33957271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of, and natural history among, individuals with Rome IV functional bowel disorders.
    Goodoory VC; Houghton LA; Black CJ; Ford AC
    Neurogastroenterol Motil; 2022 May; 34(5):e14268. PubMed ID: 34532930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtypes of irritable bowel syndrome on Rome III criteria: a multicenter study.
    Yao X; Yang YS; Cui LH; Zhao KB; Zhang ZH; Peng LH; Guo X; Sun G; Shang J; Wang WF; Feng J; Huang Q
    J Gastroenterol Hepatol; 2012 Apr; 27(4):760-5. PubMed ID: 21929652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subtypes of irritable bowel syndrome in children and adolescents.
    Self MM; Czyzewski DI; Chumpitazi BP; Weidler EM; Shulman RJ
    Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1468-73. PubMed ID: 24486406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional constipation masked as irritable bowel syndrome.
    Tosto M; D'Andrea P; Salamone I; Pellegrino S; Costa S; Lucanto MC; Pallio S; Magazzu' G; Guandalini S
    BMC Gastroenterol; 2020 Apr; 20(1):86. PubMed ID: 32252644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classification of pediatric functional gastrointestinal disorders related to abdominal pain using Rome III vs. Rome IV criterions.
    Edwards T; Friesen C; Schurman JV
    BMC Gastroenterol; 2018 Mar; 18(1):41. PubMed ID: 29549882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of the Diary for Irritable Bowel Syndrome Symptoms to Assess Treatment Benefit in Clinical Trials: Foundational Qualitative Research.
    Fehnel SE; Ervin CM; Carson RT; Rigoni G; Lackner JM; Coons SJ;
    Value Health; 2017 Apr; 20(4):618-626. PubMed ID: 28408004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Latent class analysis does not support the existence of Rome IV functional bowel disorders as discrete entities.
    Black CJ; Houghton LA; Ford AC
    Neurogastroenterol Motil; 2022 Nov; 34(11):e14391. PubMed ID: 35531932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment.
    Palsson OS; Baggish JS; Turner MJ; Whitehead WE
    Am J Gastroenterol; 2012 Feb; 107(2):286-95. PubMed ID: 22068664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of functional bowel disorder patients: a cross-sectional survey using the Rome III criteria.
    Ford AC; Bercik P; Morgan DG; Bolino C; Pintos-Sanchez MI; Moayyedi P
    Aliment Pharmacol Ther; 2014 Feb; 39(3):312-21. PubMed ID: 24308816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irritable Bowel Syndrome: Straightening the road from the Rome criteria.
    Camilleri M
    Neurogastroenterol Motil; 2020 Nov; 32(11):e13957. PubMed ID: 32808411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A comparison between Rome III and Rome II criteria in diagnosing irritable bowel syndrome].
    Wang AJ; Liao XH; Hu PJ; Liu SC; Xiong LS; Chen MH
    Zhonghua Nei Ke Za Zhi; 2007 Aug; 46(8):644-7. PubMed ID: 17967234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overlap of Rome IV Irritable Bowel Syndrome and Functional Dyspepsia and Effect on Natural History: A Longitudinal Follow-Up Study.
    Barberio B; Yiannakou Y; Houghton LA; Black CJ; Savarino EV; Ford AC
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):e89-e101. PubMed ID: 33839276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How the Change in IBS Criteria From Rome III to Rome IV Impacts on Clinical Characteristics and Key Pathophysiological Factors.
    Aziz I; Törnblom H; Palsson OS; Whitehead WE; Simrén M
    Am J Gastroenterol; 2018 Jul; 113(7):1017-1025. PubMed ID: 29880963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care.
    Black CJ; Craig O; Gracie DJ; Ford AC
    Gut; 2021 Jun; 70(6):1110-1116. PubMed ID: 32973070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Irritable bowel syndrome in the Russian Federation: results of the ROMERUS multicenter observational study].
    Maev IV; Okhlobystina OZ; Khalif IL; Andreev DN
    Ter Arkh; 2023 Feb; 95(1):38-51. PubMed ID: 37167114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.